Retre-Gel Shortage: What Providers and Prescribers Need to Know in 2026

Retre-Gel — a 20% benzocaine topical anesthetic gel — is a staple of many dental practices. Whether used to pre-anesthetize the injection site before infiltrative anesthesia, ease patient discomfort during impressions or prophylaxis, or provide short-term mucosal pain relief, benzocaine topical gels are standard clinical tools. However, the availability landscape for these products has shifted meaningfully in recent years due to FDA regulatory actions and distribution channel changes. This guide is designed to keep you informed and prepared.

FDA Shortage Status: Is Retre-Gel Officially in Shortage?

No. As of 2026, Retre-Gel and benzocaine topical gel products are not listed on the FDA's Drug Shortage Database. There are no manufacturer-reported production disruptions or shortfalls requiring official shortage designation. However, providers in some regions have reported difficulty sourcing Retre-Gel specifically through their usual dental supply distributors, a pattern consistent with localized stocking gaps rather than a supply chain crisis.

Key FDA Regulatory Actions Affecting Benzocaine Products

Providers should be aware of two major FDA regulatory actions that have shaped benzocaine product availability and labeling in recent years:

1. 2018 Methemoglobinemia Safety Communication

In May 2018, the FDA issued a Drug Safety Communication warning of the risk of serious and potentially fatal methemoglobinemia associated with topical benzocaine products. The FDA estimated that over 400 cases had been reported to FAERS since 1971, with more than 75% involving life-threatening outcomes and 7 deaths. The FDA took three key actions:

Urged OTC manufacturers to stop marketing benzocaine for teething in infants and children under 2 years old

Required standardized methemoglobinemia contraindication warnings on all OTC benzocaine product labels

Required standardized methemoglobinemia warnings in prescribing information for all prescription local anesthetics

As a clinical reminder: patients at elevated risk for methemoglobinemia include those with heart disease, G6PD deficiency, hemoglobin-M disease, NADH-methemoglobin reductase deficiency, respiratory conditions (asthma, COPD, emphysema), elderly patients, and smokers. The American Society of Anesthesiologists recommends monitoring high-risk patients using co-oximetry and having resuscitation equipment and methylene blue available when using benzocaine in procedural settings.

2. Benzocaine Spray Recalls for Benzene Contamination

Several 20% benzocaine aerosol spray formulations have been recalled due to benzene contamination detected in routine quality testing. While gel formulations like Retre-Gel have not been subject to these recalls, the withdrawals of spray products have contributed to reduced benzocaine product diversity in the market and may have affected distributors' overall stocking decisions.

39,483+ patients found their medications in stock

39K+

Find Retre-Gel In Stock Today →

Clinically Equivalent Alternatives to Retre-Gel for Your Practice

If your preferred distributor cannot supply Retre-Gel, the following products are clinically equivalent 20% benzocaine dental gels:

Hurricaine Gel (Beutlich Pharmaceuticals) — 20% benzocaine; multiple flavors; widely distributed; available through Henry Schein, Patterson, and Darby Dental.

Benzo-Jel — 20% benzocaine; professional dental gel; multiple flavors; Rx only.

Topex (Sultan Healthcare) — 20% benzocaine; widely available through dental distributors.

BeeGentle (CAO Group) — unique time-release 20% benzocaine film; ethanol-based; releases anesthetic over 20–30 minutes; Rx only.

Non-Benzocaine Alternatives for Patients Contraindicated for Benzocaine

For patients with known benzocaine or PABA hypersensitivity, high methemoglobinemia risk, or pregnancy, consider amide-type topical anesthetics:

Lidocaine 2% viscous solution — available as Rx; commonly used for mucosal anesthesia; safer pregnancy profile (Category B).

Lidocaine 4% topical solution — effective for mucosal pre-anesthesia; available through dental supply chains.

Cetacaine (benzocaine + tetracaine + butamben) — combination topical anesthetic with broad mucosal application; Rx only; note that it still contains benzocaine so is not appropriate for PABA-allergic patients.

Skip the calls, skip the stress.

Find Retre-Gel In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Sourcing Strategies for Dental Practices

To prevent disruption to your practice workflow:

Maintain a 30–60 day buffer inventory of topical anesthetic gel, especially during periods of reported supply chain uncertainty.

Establish relationships with at least two dental supply distributors so you have a backup source if your primary vendor is out of stock.

Identify two or three equivalent 20% benzocaine gel brands your practice will accept as substitutes — specify these in your formulary or procurement policies.

Monitor the FDA Drug Shortage Database and FDA MedWatch for new benzocaine product alerts, recalls, or communications.

How medfinder Supports Providers

When your patients need to fill a prescription and can't locate it at their pharmacy, medfinder for providers offers a practical solution. Your patients provide their medication and location, and medfinder calls pharmacies near them to check availability. Results are texted to the patient, removing the burden of calling multiple pharmacies from both the patient and your staff. This is particularly valuable for patients managing specialty or hard-to-find formulations.

For more on supporting your patients, see our provider's guide to helping patients find Retre-Gel.